Cardiac reverse remodelling with vericiguat: Victory or no victory?
Eur J Heart Fail
.
2023 Jul;25(7):1022-1024.
doi: 10.1002/ejhf.2883.
Epub 2023 May 25.
Authors
Muhammad Shahzeb Khan
1
,
Paul A Grayburn
2
,
Javed Butler
3
4
Affiliations
1
Division of Cardiology, Duke University, Durham, NC, USA.
2
Baylor Scott and White Heart Hospital Plano, Plano, TX, USA.
3
Baylor Scott and White Research Institute, Dallas, TX, USA.
4
Department of Medicine, University of Mississippi, Jackson, MS, USA.
PMID:
37191077
DOI:
10.1002/ejhf.2883
No abstract available
Publication types
Editorial
Comment
MeSH terms
Heart
Heart Failure*
Heterocyclic Compounds, 2-Ring*
Humans
Pyrimidines
Substances
vericiguat
Heterocyclic Compounds, 2-Ring
Pyrimidines
Associated data
ClinicalTrials.gov/NCT05093933